Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis

DEBORAH KUK, ALEXANDER N. SHOUSHTARI, CHRISTOPHER A. BARKER, KATHERINE S. PANAGEAS, RODRIGO R. MUNHOZ, PARISA MONTAZ, CHARLOTTE E. ARYAN, MARY SUE BRADY, DANIEL G. COIT, KITA BOGATCH, MARGARET K. CALLAHAN, JEDD D. WOLCHOK, RICHARD D. CARVAJAL, MICHAEL A. POSTOW

Departments of Epidemiology and Biostatistics, Medicine, Radiation Oncology, and Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Weill Cornell Medical College, New York, New York, USA; Columbia University College of Physicians and Surgeons, New York, New York, USA

Disclosures of potential conflicts of interest may be found at the end of this article.

Key Words. Mucosal melanoma • Uveal melanoma • Acral cutaneous melanoma • Nonacral cutaneous melanoma • Unknown primary melanoma • Prognosis

ABSTRACT

Background. Subtypes of melanoma, such as mucosal, uveal, and acral, are believed to result in worse prognoses than nonacral cutaneous melanoma. After a diagnosis of distant metastatic disease, however, the overall survival of patients with mucosal, uveal, acral, and unknown primary melanoma has not been directly compared.

Materials and Methods. We conducted a single-center, retrospective analysis of 3,454 patients with melanoma diagnosed with distant metastases from 2000 to 2013, identified from a prospectively maintained database. We examined melanoma subtype, date of diagnosis of distant metastases, age at diagnosis of metastasis, gender, and site of melanoma metastases.

Results. Of the 3,454 patients (237 with mucosal, 286 with uveal, 2,292 with nonacral cutaneous, 105 with acral cutaneous, and 534 with unknown primary melanoma), 2,594 died. The median follow-up was 46.1 months. The median overall survival for those with mucosal, uveal, acral, nonacral cutaneous, and unknown primary melanoma was 9.1, 13.4, 11.4, 11.7, and 10.4 months, respectively. Patients with uveal melanoma, cutaneous melanoma (acral and nonacral), and unknown primary melanoma had similar survival, but patients with mucosal melanoma had worse survival. Patients diagnosed with metastatic melanoma in 2006–2010 and 2011–2013 had better overall survival than patients diagnosed in 2000–2005. In a multivariate model, patients with mucosal melanoma had inferior overall survival compared with patients with the other four subtypes.

Conclusion. Additional research and advocacy are needed for patients with mucosal melanoma because of their shorter overall survival in the metastatic setting. Despite distinct tumor biology, the survival was similar for those with metastatic uveal melanoma, acral, nonacral cutaneous, and unknown primary melanoma.

The Oncologist 2016;21:848–854

Implications for Practice: Uveal, acral, and mucosal melanoma are assumed to result in a worse prognosis than nonacral cutaneous melanoma or unknown primary melanoma. No studies, however, have been conducted assessing the overall survival of patients with these melanoma subtypes starting at the time of distant metastatic disease. The present study found that patients with uveal, acral, nonacral cutaneous, and unknown primary melanoma have similar overall survival after distant metastases have been diagnosed. These findings provide information for oncologists to reconsider previously held assumptions and appropriately counsel patients. Patients with mucosal melanoma have worse overall survival and are thus a group in need of specific research and advocacy.

INTRODUCTION

Melanoma most commonly arises from melanocytes present in cutaneous primary locations (cutaneous melanoma), but it can occasionally arise from melanocytes located within the mucosal surfaces of the body (mucosal melanoma) and the uvea of the eye (uveal melanoma). Melanoma can also arise from cutaneous locations in non-hair-bearing surfaces (acral melanoma), such as the palms of the hands, the soles of the feet, or subungual areas. In other cases, melanoma is
diagnosed in the metastatic setting without a known primary site (unknown primary melanoma).

Mucosal, uveal, and acral melanoma are far less common than nonacral cutaneous melanoma and have distinct clinical and biological features [1–4]. Cutaneous melanoma has a high frequency of mutations in the oncogene BRAF, and mucosal and acral melanomas have a higher proportion of mutations in the receptor tyrosine kinase protein, KIT [3, 4]. Uveal melanomas, in contrast, have a high proportion of mutations in GNAQ and GNA11, which encode for the α-subunit protein of the heterotrimeric G protein complex activating phospholipase C [5]. The etiology of unknown primary melanoma is not known, but spontaneous regression of an otherwise unrecognized cutaneous melanoma could be involved [6]. The molecular profiles of unknown primary melanoma most closely resemble nonacral cutaneous melanoma, supporting this possibility [7, 8].

It is generally believed that melanoma arising from a mucosal, uveal, or acral cutaneous primary location portends a worse overall prognosis than melanoma arising from a nonacral cutaneous primary location. This assumption has largely been based on studies that have reported high recurrence rates after definitive treatment of primary mucosal, uveal, and acral melanoma and poor overall survival from the time of the diagnosis of primary disease to death [9–14]. Despite these prognostic assertions, no study, to the best of our knowledge, has evaluated whether the outcomes of patients with these various melanoma subtypes differ after the diagnosis of metastatic disease.

We reviewed the Memorial Sloan Kettering Cancer Center experience of patients who had been diagnosed with distant metastatic mucosal, uveal, acral, nonacral cutaneous, and unknown primary melanoma during a 14-year period (2000–2013). We analyzed overall survival among these melanoma subtypes from the time of metastasis diagnosis to death and investigated the relationships between the known prognostic variables and outcome.

**Materials and Methods**

Patients (n = 3,454) who had been diagnosed with distant metastatic mucosal, uveal, acral, nonacral cutaneous, and unknown primary melanoma were identified from our prospectively maintained melanoma database. The date of diagnosis of distant metastasis was defined as the date distant metastases first appeared clinically or radiographically. The date of each patient’s last known follow-up appointment or death was also recorded. Data on age, gender, treatment with agents known to prolong overall survival in the era of the study (i.e., ipilimumab, vemurafenib, dabrafenib, trametinib, pembrolizumab, and nivolumab), and site of metastases (skin/lymph node involvement, lung metastases, nonpulmonary visceral metastases) were extracted. Patients with mucosal and nonacral cutaneous melanoma were further analyzed according to the specific anatomic subsite of their primary melanoma (mucosal: anorectal, head/neck, vulvovaginal, and other; nonacral cutaneous: scalp, head/neck nonscalp, upper extremity, lower extremity, and trunk). The present retrospective analysis was performed after institutional review board determination that it was exempt research under 45 Code of Federal Regulations 46.101.b.

**Statistical Analysis**

The chi-square test and the Kruskal-Wallis test were used to compare the patient and disease characteristics among the melanoma subtypes for categorical and continuous variables, respectively. Overall survival was defined as the time from the date of metastatic diagnosis to the date of death or the last follow-up visit. The Kaplan-Meier method was used, and comparisons between categorical variables were assessed using the log-rank test. A Cox proportional hazards model was used for multivariate analysis. Because treatment with agents proven to improve overall survival increased over time, most dramatically beginning in 2006 (with U.S. Food and Drug Administration approvals starting in 2011), the year of metastatic diagnosis was included as a variable and categorized as 2000–2005, 2006–2010, and 2011–2013. p values <.05 were considered significant. All analyses were performed using R, version 3.1.1 (available at https://cran.r-project.org).

**Results**

**Patient Demographics and Treatment**

A total of 3,454 patients with metastatic melanoma of primary mucosal (n = 237), uveal (n = 286), acral (n = 105), nonacral cutaneous (n = 2,292), and unknown primary (n = 534) melanoma were included in the present analysis (Table 1). Patients with mucosal melanoma were slightly older, with a median age of 66 years, compared with patients with uveal, acral, nonacral cutaneous, and unknown primary melanoma (median age of 63, 65, 62, and 61 years, respectively; p < .001). More women than men had mucosal melanoma, largely driven by the cases of vulvovaginal melanoma, but more men than women had the other four subtypes (p < .001). Among all melanoma subtypes, the proportion of patients with nonpulmonary visceral metastases (60%) at the time of metastatic diagnosis was greater than that of patients with pulmonary (27%) and skin/lymph node (13%) metastatic melanoma. This difference appeared largest in patients with uveal melanoma, with 87% diagnosed with nonpulmonary visceral melanoma metastases (p < .001). Additional demographic details of the study population are presented in Table 1.

Very few patients diagnosed with metastatic melanoma from 2000 to 2005 received treatment shown to improve overall survival (ipilimumab, 3%; RAF inhibitor, <1%; trametinib, 0%; pembrolizumab or nivolumab monotherapy, 0%; Table 2). These proportions differed in the cohort diagnosed with metastatic disease from 2006 to 2010 (ipilimumab, 22%; RAF inhibition, 4%; trametinib, <1%; pembrolizumab or nivolumab monotherapy, 1%; ipilimumab plus nivolumab, <1%) and from 2011 to 2013 (ipilimumab, 53%; RAF inhibitor, 17%; trametinib, 3%; pembrolizumab or nivolumab monotherapy, 7%; ipilimumab plus nivolumab, 4%).

**Univariate Analysis of Overall Survival**

At the last follow-up point, 860 of the 3,454 patients were still alive. The median follow-up period for the survivors was 46.1 months. The median overall survival for the entire cohort of patients was 11.4 months. The univariate analysis results are presented in Table 3. Patients with mucosal melanoma had a significantly shorter median overall survival than that of
patients with uveal, acral, nonacral cutaneous, and unknown primary melanoma (9.1, 13.4, 11.4, 11.7, and 10.4 months, respectively; \( p \leq .001; \) Fig. 1). No significant differences were seen in survival between patients with uveal melanoma, both types of cutaneous melanoma (acral and nonacral), and unknown primary melanoma (\( p = .972 \)). The overall survival also did not differ between those with acral and nonacral cutaneous melanoma (\( p = .891 \)).

We next sought to determine whether differences could be found in overall survival among patients whose metastatic melanoma had arisen from a specific primary anatomic location. No difference was seen in survival among the specific anatomic subtypes of mucosal melanoma (\( p = .34 \); Table 3). However, a significant difference was found in survival among patients with nonacral cutaneous melanoma according to their specific anatomic primary subsite. Patients whose melanoma had originally arisen from a truncal location had worse metastatic overall survival than patients whose cutaneous primary melanoma had arisen from other sites (\( p = .02 \); Table 3).

Older age was associated with decreased survival (\( p < .001 \)). Patients with nonpulmonary visceral metastases had significantly worse survival (8.8 months) than patients with...

### Table 1. Patient demographics

<table>
<thead>
<tr>
<th>Variable</th>
<th>All patients</th>
<th>Mucosal</th>
<th>Uveal</th>
<th>Nonacral cutaneous</th>
<th>Acral cutaneous</th>
<th>Unknown primary</th>
<th>( p ) value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total (n)</td>
<td>3,454</td>
<td>237</td>
<td>286</td>
<td>2,292</td>
<td>105</td>
<td>534</td>
<td></td>
</tr>
<tr>
<td>Median age (yr; range)</td>
<td>62 (3–97)</td>
<td>66 (26–91)</td>
<td>63 (16–86)</td>
<td>62 (3–97)</td>
<td>65 (31–90)</td>
<td>61 (4–92)</td>
<td>&lt; .001</td>
</tr>
<tr>
<td>Gender, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt; .001</td>
</tr>
<tr>
<td>Female</td>
<td>1,301 (38)</td>
<td>155 (65)</td>
<td>131 (46)</td>
<td>772 (34)</td>
<td>45 (43)</td>
<td>198 (37)</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>2,153 (62)</td>
<td>82 (35)</td>
<td>155 (54)</td>
<td>1,520 (66)</td>
<td>60 (57)</td>
<td>336 (63)</td>
<td></td>
</tr>
<tr>
<td>Metastatic location, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt; .001</td>
</tr>
<tr>
<td>Skin/lymph node</td>
<td>438 (13)</td>
<td>19 (8)</td>
<td>13 (5)</td>
<td>311 (14)</td>
<td>24 (23)</td>
<td>71 (13)</td>
<td></td>
</tr>
<tr>
<td>Pulmonary</td>
<td>948 (27)</td>
<td>50 (21)</td>
<td>23 (8)</td>
<td>717 (31)</td>
<td>38 (36)</td>
<td>120 (22)</td>
<td></td>
</tr>
<tr>
<td>Nonpulmonary visceral</td>
<td>2,068 (60)</td>
<td>168 (71)</td>
<td>250 (87)</td>
<td>1,264 (55)</td>
<td>43 (41)</td>
<td>343 (64)</td>
<td></td>
</tr>
<tr>
<td>Year of metastatic diagnosis, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.012</td>
</tr>
<tr>
<td>2000–2005</td>
<td>1,351 (39)</td>
<td>97 (8)</td>
<td>109 (38)</td>
<td>912 (40)</td>
<td>29 (28)</td>
<td>204 (38)</td>
<td></td>
</tr>
<tr>
<td>2006–2010</td>
<td>1,273 (37)</td>
<td>88 (37)</td>
<td>92 (32)</td>
<td>862 (38)</td>
<td>38 (36)</td>
<td>193 (36)</td>
<td></td>
</tr>
<tr>
<td>2011–2013</td>
<td>830 (24)</td>
<td>52 (22)</td>
<td>85 (30)</td>
<td>518 (22)</td>
<td>38 (36)</td>
<td>137 (26)</td>
<td></td>
</tr>
</tbody>
</table>

### Table 2. Treatment stratified by melanoma subtype and year of metastatic diagnosis

<table>
<thead>
<tr>
<th>Variable</th>
<th>Total</th>
<th>Ipilimumab*</th>
<th>Vermutafenib or dabrafenib</th>
<th>Trametinib</th>
<th>Pembrolizumab or nivolumab</th>
<th>Ipilimumab plus nivolumab</th>
</tr>
</thead>
<tbody>
<tr>
<td>2000–2005</td>
<td>1,351</td>
<td>34 (3)</td>
<td>7 (&lt;1)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Mucosal</td>
<td>97</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Uveal</td>
<td>109</td>
<td>2 (2)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Nonacral cutaneous</td>
<td>912</td>
<td>25 (3)</td>
<td>5 (&lt;1)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Acral cutaneous</td>
<td>29</td>
<td>1 (3)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Unknown primary</td>
<td>204</td>
<td>6 (3)</td>
<td>2 (&lt;1)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>2006–2010</td>
<td>1,273</td>
<td>274 (22)</td>
<td>53 (4)</td>
<td>3 (&lt;1)</td>
<td>19 (1)</td>
<td>6 (&lt;1)</td>
</tr>
<tr>
<td>Mucosal</td>
<td>88</td>
<td>13 (15)</td>
<td>1 (1)</td>
<td>0 (0)</td>
<td>1 (1)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Uveal</td>
<td>92</td>
<td>23 (25)</td>
<td>0 (0)</td>
<td>2 (2)</td>
<td>2 (2)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Nonacral cutaneous</td>
<td>862</td>
<td>189 (22)</td>
<td>42 (5)</td>
<td>1 (&lt;1)</td>
<td>12 (1)</td>
<td>5 (&lt;1)</td>
</tr>
<tr>
<td>Acral cutaneous</td>
<td>38</td>
<td>15 (39)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>2 (5)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Unknown primary</td>
<td>193</td>
<td>34 (18)</td>
<td>10 (5)</td>
<td>0 (0)</td>
<td>2 (1)</td>
<td>1 (&lt;1)</td>
</tr>
<tr>
<td>2011–2013</td>
<td>830</td>
<td>436 (53)</td>
<td>138 (17)</td>
<td>26 (3)</td>
<td>64 (7)</td>
<td>30 (4)</td>
</tr>
<tr>
<td>Mucosal</td>
<td>52</td>
<td>35 (67)</td>
<td>1 (2)</td>
<td>0 (0)</td>
<td>8 (15)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Uveal</td>
<td>85</td>
<td>27 (32)</td>
<td>0 (0)</td>
<td>9 (11)</td>
<td>4 (5)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Nonacral cutaneous</td>
<td>518</td>
<td>285 (55)</td>
<td>108 (21)</td>
<td>11 (2)</td>
<td>34 (7)</td>
<td>27 (5)</td>
</tr>
<tr>
<td>Acral cutaneous</td>
<td>38</td>
<td>20 (53)</td>
<td>5 (13)</td>
<td>1 (3)</td>
<td>7 (18)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Unknown primary</td>
<td>137</td>
<td>69 (50)</td>
<td>24 (18)</td>
<td>5 (4)</td>
<td>11 (8)</td>
<td>3 (2)</td>
</tr>
</tbody>
</table>

Data presented as \( n \) (%).

*Treatment administered as a single agent.
metastatic melanoma involving skin/lymph node (17.5 months) and pulmonary (16.1 months) locations (p < .001).

Although a significant difference was found in gender by melanoma subtype, no significant difference was found in survival by gender. Patients whose metastatic diagnosis was in 2006–2010 and 2011–2013 had higher median survival than patients with a metastatic diagnosis in 2000–2005 (median overall survival, 12.0, 14.5, and 9.8 months, respectively; p < .001; Fig. 2). In the 2011–2013 period, the same pattern of survival was observed (Fig. 3). The median overall survival was similar between the uveal and nonacral cutaneous patients (13.9 and 14.7 months, respectively; p = .736), although most of the nonacral cutaneous patients had received immunotherapy or targeted drugs. Patients with mucosal melanoma had significantly worse overall survival (median overall survival, 7.5 months) compared with those with nonacral cutaneous melanoma (p < .001).

Multivariate Analysis of Overall Survival

Because age, location of metastases, and year of metastatic diagnosis were significantly associated with survival on univariate analysis, these factors were incorporated into a multivariate model. Although gender was not associated with overall survival in our univariate analysis, it was included in the multivariate model, because previous analyses had reported that it was related to the overall survival of patients with melanoma [15, 16].

On multivariate analysis, melanoma subtype, age, site of metastases, and year of metastatic diagnosis were significantly associated with overall survival (Table 4). Similar to the univariate results, those with nonacral cutaneous (hazard ratio [HR], 0.80), uveal melanoma (HR, 0.70), acral cutaneous (HR, 0.90), and unknown primary (HR, 0.78) melanoma had better overall survival than did those with mucosal melanoma.

**DISCUSSION**

In the present retrospective analysis of nearly 3,500 patients with metastatic melanoma and long-term follow-up data available, we found that metastatic melanoma arising from a primary mucosal site was independently associated with shorter overall survival. Patients with metastatic uveal, acral cutaneous, nonacral cutaneous, and unknown primary melanoma, however,
had similar overall survival. Follow-up was complete, with 2,594 deaths (75%) of an initial 3,454 patients at risk, and the median follow-up period for the survivors was long at 46.1 months.

Although other studies have suggested that patients with mucosal, uveal, and acral cutaneous melanoma have a worse prognosis than those with nonacral cutaneous melanoma [9–14], the present study is the only one, to the best of our knowledge, in which the prognosis of metastatic patients with these various melanoma subtypes was directly compared. We found that patients with distant metastatic melanoma of an unknown primary had similar outcomes compared with patients with melanoma of a known primary, consistent with some [17], but not all [18, 19], other studies assessing unknown primary melanoma and melanoma of known primary. Differences in patient numbers and study methods could account for some of the variation.

During the time period of our analysis, several new agents were introduced that were shown to improve overall survival, including ipilimumab [20, 21], vemurafenib [22], dabrafenib [23], trametinib [24], pembrolizumab [25], and nivolumab [26]. It is possible these new treatments affected the improved outcomes seen in the latter time groups, but many factors could have been involved in this finding and the follow-up time was shorter. Nonetheless, when we divided the patients into three subgroups according to the timeframe of their distant disease diagnosis, our main conclusion of the mucosal subtype being associated with shorter overall survival remained unchanged. The finding of worse overall survival for patients with mucosal melanoma compared with nonacral cutaneous melanoma was impressive within the 2011–2013 cohort (7.5 months vs. 14.7 months, respectively; \( p < .001 \)), suggesting that this difference still seems to exist within more contemporary clinical practice patterns in treatment. Because mucosal and uveal melanomas are associated with a lower frequency of \( BRAF \) mutations than cutaneous melanoma [3], the rate of RAF inhibitor use was higher in patients with cutaneous melanoma. Although this might have led to slightly favorable results in the cutaneous group, the rate of RAF inhibitor use was still low, likely because of the historical period when most of these patients were diagnosed with metastatic disease and the unavailability of RAF inhibitors. The use of anti-programmed death 1 (PD-1) inhibitors and the combination of ipilimumab plus nivolumab was low in all study periods. Even in the most recent cohort, 2011–2013, although the numbers were small, the use of anti-PD-1 antibodies was not substantially lower in patients with mucosal melanoma to believe this was a reason for their inferior overall survival. When
The reason patients with metastatic mucosal melanoma had worse overall survival remains unclear. Unlike cutaneous melanoma, which has a high somatic mutation rate and mutations associated with exposure to UV light [36, 37], mucosal melanoma has a lower somatic mutation rate with genetic copy number and structural variants that differ from the mutations typically seen in melanomas associated with UV light [38]. It is possible that the unique genetic profile of mucosal melanomas contributes to an inherently more aggressive course than cutaneous melanoma, but this requires further study.

**CONCLUSION**

These prognostic findings highlight the need for additional research, patient advocacy, and inclusion in clinical trials of new agents for patients with mucosal melanoma as little is known about the responsiveness of mucosal melanoma to novel melanoma therapeutics. Although metastatic uveal melanoma is believed to be less responsive to systemic therapies than cutaneous melanoma, in our data set, patients with uveal melanoma had the same overall survival as patients with cutaneous melanoma. The prognoses of patients with other malignancies that consist of various subtypes should be similarly investigated from the time of metastatic disease because the prognoses could differ from those when the overall survival from early-stage disease to death is assessed.

**ACKNOWLEDGMENTS**

This study was funded by Core Grant P30 CA008748. This work was previously presented in part at the 50th Annual Meeting of the American Society of Clinical Oncology, May 30–June 3, 2014.

**AUTHOR CONTRIBUTIONS**

Conception/design: Deborah Kuk, Richard D. Carvajal, Michael A. Postow

Provision of study material or patients: Alexander N. Shoushtari, Katherine S. Panageas, Mary Sue Brady, Kita Bogatch, Margaret K. Callahan, Jedd D. Wolchok, Richard D. Carvajal, Michael A. Postow

Collection and/or assembly of data: Deborah Kuk, Katherine S. Panageas, Daniel G. Coit, Kita Bogatch, Michael A. Postow

Data analysis and interpretation: Deborah Kuk, Katherine S. Panageas, Kita Bogatch, Richard D. Carvajal, Michael A. Postow

Manuscript writing: Deborah Kuk, Alexander N. Shoushtari, Christopher A. Barker, Katherine S. Panageas, Rodrigo R. Munhoz, Parisa Montaz, Charlotte E. Ariyan, Mary Sue Brady, Daniel G. Coit, Kita Bogatch, Margaret K. Callahan, Jedd D. Wolchok, Richard D. Carvajal, Michael A. Postow

Final approval of manuscript: Deborah Kuk, Alexander N. Shoushtari, Christopher A. Barker, Katherine S. Panageas, Rodrigo R. Munhoz, Parisa Montaz, Charlotte E. Ariyan, Mary Sue Brady, Daniel G. Coit, Kita Bogatch, Margaret K. Callahan, Jedd D. Wolchok, Richard D. Carvajal, Michael A. Postow

**DISCLOSURES**

Alexander N. Shoushtari: Vaccinex (C/A), Bristol-Myers Squibb (RF); Christopher A. Barker: Elekta, Patient Resource (C/A), Elekta (RF); Rodrigo R. Munhoz: Bristol-Myers Squibb, MSD (H), Eli Lilly (RF); Margaret K. Callahan: Bristol-Myers Squibb (E [spouse]), Bristol-Myers Squibb (RF); Jedd D. Wolchok: Bristol-Myers Squibb, Merck, Medimmune, Genentech, Zelboraf, Polaris, Beigene (RF), Potenza Therapeutics, Tizona Pharmaceuticals (OI); Richard D. Carvajal: Merck, AstraZeneca, Novartis, Janssen IC(A); Michael A. Postow: Bristol-Myers Squibb, Caladrius (C/A), Bristol-Myers Squibb, Merck (H), Bristol-Myers Squibb, Merck, Novartis (RF). The other authors indicated no financial relationships.

(C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert testimony; (H) Honoraria received; (OI) Ownership interests; (IP) Intellectual property rights/inventor/patent holder; (SAB) Scientific advisory board.
REFERENCES